Skip to main content
Delfa

← All assets

Butylphthalide

4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

4

Ongoing

1

Recruiting

0

Completed

1

Sites

4

Countries

1

Endpoints

38

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 38 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2/3
1
Phase 3
1
Not applicable
2

Trials by status

Active, not recruiting
1
Completed
1
Unknown
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Executive function / language
8
Global cognition
7
Behavior / neuropsychiatric
5
Neuroimaging
5
Other (unclassified)
5
Function / daily living
3
Memory
2
Fluid / digital biomarkers
1
Caregiver / quality of life
1
Other clinical outcomes
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 10 of 38 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

3

Mini-Mental State Examination (MMSE)Cognition

2

ADAS-CogCognition

2

ADCS-Activities of Daily Living (ADCS-ADL)Function

2

Montreal Cognitive Assessment (MoCA)Cognition

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

4 of 4

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
EBSCPVCINDThe Efficacy of Butylphthalide Soft Capsules in Patents With VCIND

Butylphthalide

Vascular cognitive impairment / dementia

MMSE ≥24Ph 2/3Unknown1Jan 20191
NCT03906123The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia

Butylphthalide

Vascular cognitive impairment / dementia

MMSE 15Not applicableUnknown1Dec 2019-
NCT03804229Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia

Butylphthalide

Vascular cognitive impairment / dementia

Vascular dementiaPh 3Active, not recruiting1Oct 2024-
NCT02711683DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil

Butylphthalide, Donepezil

Alzheimer’s disease

Alzheimer's diseaseNot applicableCompleted1Dec 2019-

Showing 1-4 of 4 trials